In the New Yorker today – HCV News April 24, 2014
Posted by voolavex in common sense, Economics, Health, health care, Medical, Social Issues.Tags: cost, Cure, HCV, James Surowiecki, The New Yorker
trackback
The day after my post: The Cure. Your Liver. $84.000. The brilliant financial author James Surowiecki, wrote a piece on the Financial Page (p23) in the New Yorker. entitled “Biotech’s Hard Bargain”. I am most grateful to read a piece on the cost of HCV in such a prestigious and well read publication. He brings a much needed reinforcement to the arguments of others who find the $84,000 price tag distressing. In his piece he points out that Medicare is forbidden to bargain for better prices for drugs and that private insurers are very upset and pharmacy benefit companies are suggesting their customers wait for a cheaper “cure”. Pharma has tremendous pricing power and this is one of the lures for investors. Rather than dropping price, pharmaceuticals actually increase. Wonder leukemia drug, Gleevac, has tripled since 2001. I would strongly suggest you read Mr. Surowiecki’s piece and see for yourself. Some people want to wait until it is cheaper, but others simply can’t wait – and are on donor lists in serious need of a fix of any kind. I am grateful to have my observations reiterated in this post. Thanks James. The New Yorker is online, on newsstands and in the library – I invite you to read the Financial Page and my own post. And I wish all of you good health – at a price you can afford.
Voolavex 
Comments»
No comments yet — be the first.